RxDoctor Payments DataLook up a doctor →

James Wolfe, MD

Allergy & Immunology · San Jose, CANPI 1194733428

Payments from drug & device makers

$2,543,381in general payments, 2019–2025

Across 590 payments — averaging $4310.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$934K
  • Teva Pharmaceuticals USA, Inc.$496K
  • Amphastar Pharmaceuticals, Inc.$355K
  • Chiesi USA, Inc.$192K
  • Cipla USA Inc.$185K
  • Astrazeneca UK Limited$160K
  • plus $221K from 27 others

What the payments were for

  • Speaking & faculty fees$170,23795%
  • Travel & lodging$2390%
  • Food & beverage$7,8554%
  • Education$310%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,543,381 in reported general payments places this provider in the 95th percentile of 426 allergy & immunology providers in California.

See all allergy & immunology providers in California

Medicare billing

Part B allowed, 2024
$351,045
Medicare patients
745
Services billed
17,164

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent SyringeDupilumab104$402,004
Dupixent PenDupilumab95$379,061
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr150$141,233
AlvescoCiclesonide103$110,979
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5012$81,502
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$29,470
Arnuity ElliptaFluticasone Furoate39$17,144
Azelastine Hcl312$14,917
Spiriva HandihalerTiotropium Bromide16$11,680
Ipratropium Bromide254$11,501
Hydroxyzine Hcl293$10,509
Fluticasone Propionate HfaFluticasone Propionate15$7,949
Clarithromycin135$7,453
Fluticasone Propionate42$6,248
Bevespi AerosphereGlycopyrrolate/Formoterol Fum11$5,809

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKAnoro Ellipta, Trelegy Ellipta, Arnuity Ellipta$30,446$187,847210 claims
Covis Pharma GmbHAlvesco$73$110,979103 claims
AstraZenecaBevespi Aerosphere$933,999$5,80911 claims
Hikma Pharmaceuticals USAEpinephrine$72$3,66720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 426 allergy & immunology providers in California.

Other allergy & immunology in San Jose

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →